News

In this eight-week study, Cymbalta, a serotonin and norepinephrine reuptake inhibitor, was effective in reducing depression symptoms by two weeks for 42% of patients. Within the same time

Radius has also acquired the rights to the analogs of the molecule, along with rights to several Ipsen novel formulation technologies. The license is on a worldwide basis

Vertex will receive a $20 million up-front payment and could receive up to an additional $385 million in development and sales threshold milestone payments based on the development

The primary objective of the phase I study will be to evaluate the safety and tolerability of single escalating doses of SIGA-246, and will be performed at the

The filing represents the ninth milestone that the companies have achieved in the collaboration and triggers a milestone payment to Roche. In the collaboration, Genmab utilizes its antibody

Arformoterol is the first long-acting bronchodilator to be developed in an inhalation solution for use with a nebulizer. Other long-acting bronchodilators currently available are formulated in dry-powder inhalers

Postmenopausal women in the trial who switched from placebo to Femara experienced a 69% reduction in the risk that their breast cancer would return. There also was a

Iplex is specifically approved to treat children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormones. The drug

The company is to make the filing after a pivotal trial showed two years of maintenance therapy with the drug, known as Rituxan in the US, dramatically improved